Can high‑fat meals increase the absorption of Contrave (bupropion + naltrexone) and raise seizure risk?

High-Fat Meals Significantly Increase Contrave Absorption and Seizure Risk

Do not take Contrave with high-fat meals—this substantially increases drug exposure and elevates the already present seizure risk associated with bupropion. The FDA label explicitly states this contraindication based on pharmacokinetic data showing dangerous increases in systemic exposure 1.

The Pharmacokinetic Evidence

When Contrave is administered with a high-fat meal, the absorption increases are dramatic and clinically significant:

• Naltrexone exposure increases 2.1-fold (AUC) and peak levels increase 3.7-fold (Cmax)
• Bupropion exposure increases 1.4-fold (AUC) and peak levels increase 1.8-fold (Cmax)
• At steady state, these effects persist with naltrexone AUC and Cmax increasing 1.7-fold and 1.9-fold, and bupropion increasing 1.1-fold and 1.3-fold 1

This is not a minor food effect—it represents a near-doubling to quadrupling of drug exposure depending on the component measured.

Why This Matters for Seizure Risk

Bupropion carries an inherent dose-dependent seizure risk. The baseline incidence at recommended doses (≤450 mg/day) is approximately 0.35-0.44%, with a 2-year cumulative risk of 0.48% 2. However, seizure risk increases substantially with higher bupropion exposure 3, 2, 4, 5.

The mechanism is straightforward: bupropion lowers the seizure threshold, and higher blood levels amplify this effect. When high-fat meals increase bupropion exposure by 1.4 to 1.8-fold, you are effectively pushing patients toward supratherapeutic levels that carry the same risks as intentional overdosing 1.

Clinical Context from Guidelines

The 2022 AGA guidelines acknowledge this concern, stating that naltrexone-bupropion ER should be avoided in patients with seizure disorders and used with caution in patients at risk of seizures 6. The guideline provides conditional recommendation for its use specifically because of these safety concerns, despite moderate evidence for efficacy.

Practical Management Algorithm

For patients prescribed Contrave:

1. Explicitly instruct patients to avoid high-fat meals when taking the medication—this means no fatty breakfast or dinner coinciding with dosing

2. Screen for seizure risk factors before prescribing:

   • Personal or family history of seizures
   • History of head injury, brain tumor, or CNS infection
   • Eating disorders (anorexia/bulimia)
   • Alcohol abuse or abrupt alcohol cessation
   • Concurrent medications that lower seizure threshold
   • Conditions causing hypoglycemia or hyponatremia

3. If a patient inadvertently takes Contrave with a high-fat meal:

   • Monitor for signs of toxicity (agitation, tremor, confusion)
   • If seizure occurs, discontinue Contrave permanently 1
   • Do not rechallenge—seizure is an absolute contraindication to continued use

4. Dose escalation must follow the prescribed schedule (starting at 1 tablet daily, gradually increasing to 2 tablets twice daily over 4 weeks) to minimize seizure risk even under optimal conditions 1

Common Pitfalls

• Patients may not understand what constitutes a "high-fat meal"—be specific: avoid meals with significant butter, oils, fatty meats, full-fat dairy, or fried foods within 2 hours of dosing
• The food effect is bidirectional—it affects both components of Contrave, not just bupropion, though bupropion is the seizure-relevant component
• Seizures can occur even at therapeutic doses and blood levels in susceptible individuals 4, so the high-fat meal interaction adds risk on top of baseline risk

Additional Safety Considerations

Beyond seizures, the increased drug exposure from high-fat meals amplifies other adverse effects including neuropsychiatric symptoms (aggressiveness, depression, suicidal ideation), cardiovascular effects (hypertension, arrhythmias), and gastrointestinal symptoms (nausea, vomiting, constipation) that already affect 40-50% of patients at standard dosing 7, 8.

The bottom line: High-fat meals transform Contrave from a medication with manageable risks into one with substantially elevated seizure and toxicity potential. This is a firm contraindication based on FDA pharmacokinetic data, not a theoretical concern.